195 related articles for article (PubMed ID: 31113867)
21. N-methyltetrahydro-beta-carboline analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin are oxidized to neurotoxic beta-carbolinium cations by heme peroxidases.
Herraiz T; Guillén H; Galisteo J
Biochem Biophys Res Commun; 2007 Apr; 356(1):118-23. PubMed ID: 17346675
[TBL] [Abstract][Full Text] [Related]
22. Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease.
Dutta D; Ali N; Banerjee E; Singh R; Naskar A; Paidi RK; Mohanakumar KP
Mol Neurobiol; 2018 Jan; 55(1):804-821. PubMed ID: 28062948
[TBL] [Abstract][Full Text] [Related]
23. MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.
Thomas B; von Coelln R; Mandir AS; Trinkaus DB; Farah MH; Leong Lim K; Calingasan NY; Flint Beal M; Dawson VL; Dawson TM
Neurobiol Dis; 2007 May; 26(2):312-22. PubMed ID: 17336077
[TBL] [Abstract][Full Text] [Related]
24. Andrographolide alleviates Parkinsonism in MPTP-PD mice via targeting mitochondrial fission mediated by dynamin-related protein 1.
Geng J; Liu W; Gao J; Jiang C; Fan T; Sun Y; Qin ZH; Xu Q; Guo W; Gao J
Br J Pharmacol; 2019 Dec; 176(23):4574-4591. PubMed ID: 31389613
[TBL] [Abstract][Full Text] [Related]
25. Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra.
Ostergren A; Fredriksson A; Brittebo EB
J Neural Transm (Vienna); 2006 Mar; 113(3):313-29. PubMed ID: 16075188
[TBL] [Abstract][Full Text] [Related]
26. Increased vulnerability of parkin knock down PC12 cells to hydrogen peroxide toxicity: the role of salsolinol and NM-salsolinol.
Su Y; Duan J; Ying Z; Hou Y; Zhang Y; Wang R; Deng Y
Neuroscience; 2013 Mar; 233():72-85. PubMed ID: 23291452
[TBL] [Abstract][Full Text] [Related]
27. Generation of Mitochondrial Toxin Rodent Models of Parkinson's Disease Using 6-OHDA , MPTP , and Rotenone.
Maegawa H; Niwa H
Methods Mol Biol; 2021; 2322():95-110. PubMed ID: 34043196
[TBL] [Abstract][Full Text] [Related]
28. [Contribution of MPTP to studies on the pathogenesis of Parkinson's disease].
Mizuno Y
Rinsho Shinkeigaku; 1989 Dec; 29(12):1494-6. PubMed ID: 2698296
[TBL] [Abstract][Full Text] [Related]
29. Amine-related neurotoxins in Parkinson's disease: past, present, and future.
Nagatsu T
Neurotoxicol Teratol; 2002; 24(5):565-9. PubMed ID: 12200187
[TBL] [Abstract][Full Text] [Related]
30. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine as a substrate of cytochrome P450 2D6: allosteric effects of NADPH-cytochrome P450 reductase.
Modi S; Gilham DE; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
Biochemistry; 1997 Apr; 36(15):4461-70. PubMed ID: 9109653
[TBL] [Abstract][Full Text] [Related]
31. MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration.
Lee E; Hwang I; Park S; Hong S; Hwang B; Cho Y; Son J; Yu JW
Cell Death Differ; 2019 Jan; 26(2):213-228. PubMed ID: 29786072
[TBL] [Abstract][Full Text] [Related]
32. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
[TBL] [Abstract][Full Text] [Related]
33. 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets.
Perry TL; Jones K; Hansen S; Wall RA
Neurosci Lett; 1987 Mar; 75(1):65-70. PubMed ID: 3106859
[TBL] [Abstract][Full Text] [Related]
34. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
[TBL] [Abstract][Full Text] [Related]
35. Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism.
Alvarez-Fischer D; Noelker C; Grünewald A; Vulinović F; Guerreiro S; Fuchs J; Lu L; Lombès A; Hirsch EC; Oertel WH; Michel PP; Hartmann A
J Neurochem; 2013 Dec; 127(6):782-92. PubMed ID: 23802648
[TBL] [Abstract][Full Text] [Related]
36. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
[TBL] [Abstract][Full Text] [Related]
38. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease.
González H; Contreras F; Prado C; Elgueta D; Franz D; Bernales S; Pacheco R
J Immunol; 2013 May; 190(10):5048-56. PubMed ID: 23589621
[TBL] [Abstract][Full Text] [Related]
39. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients.
Mann A; Miksys SL; Gaedigk A; Kish SJ; Mash DC; Tyndale RF
Neurobiol Aging; 2012 Sep; 33(9):2160-71. PubMed ID: 21958961
[TBL] [Abstract][Full Text] [Related]
40. MPTP as a mitochondrial neurotoxic model of Parkinson's disease.
Przedborski S; Tieu K; Perier C; Vila M
J Bioenerg Biomembr; 2004 Aug; 36(4):375-9. PubMed ID: 15377875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
